Skip to content

Evaluation of the Safety of Loargys Arginine Test System in Loargys-treated Patients

A Multicenter, Prospective Study Assessing the Safety of Loargys Arginine Test System for Determining Arginine in Loargys-treated Patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07573059
Acronym
CLEAR
Enrollment
100
Registered
2026-05-07
Start date
2026-04-17
Completion date
2027-07-15
Last updated
2026-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ARG1 Deficiency

Brief summary

Arginase 1 deficiency (ARG1-D) is a rare condition in which the body cannot properly break down a substance called arginine. This leads to high levels of arginine and related substances in the blood, which can cause serious health problems and reduce quality of life. Loargys is a new treatment designed to lower arginine levels in people with ARG1-D. It works by providing a modified version of a natural enzyme that breaks down arginine in the blood. The dose of Loargys is adjusted for each patient based on their arginine levels. Because Loargys continues to break down arginine even after a blood sample has been taken, to ensure accurate results, a special substance (called nor-NOHA) is added to the blood collection tubes to stop this process after the sample is taken. The arginine levels are then measured using a standard laboratory test. The Loargys Arginine Test System used in this study includes both the special blood collection tubes and the laboratory test used to measure arginine. The purpose of this study is to evaluate the safety of this test system when used to measure arginine levels in patients receiving Loargys.

Interventions

DEVICELoargys Arginine Test System

Loargys Arginine Test System

Sponsors

Immedica Pharma US Inc
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
0 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Participant receiving treatment with commercialized Loargys for ARG1-D * Participant is willing to sign the Informed Consent Form

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frame
Incidence of AEs related to the Loargys Arginine Test SystemThrough study completion, up to 21 months

Countries

United States

Contacts

CONTACTHead of Global Integrated Evidence Generation
clinical@immedica.com+46(0)853339500
STUDY_DIRECTORMattias Rudebeck, PhD

Immedica Pharma US Inc

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 8, 2026